Postes actifs de Didier Véron
Sociétés | Poste | Début | Fin |
---|---|---|---|
Leem | Directeur/Membre du Conseil | - | - |
Historique de carrière de Didier Véron
Anciens postes connus de Didier Véron
Sociétés | Poste | Début | Fin |
---|---|---|---|
IPSEN | Public Communications Contact | 01/01/2013 | 01/12/2018 |
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Public Communications Contact | 25/08/2010 | 03/02/2014 |
Formation de Didier Véron
Sciences Po | Undergraduate Degree |
Statistiques
Internationale
France | 5 |
Etats-Unis | 2 |
Opérationnelle
Public Communications Contact | 2 |
Director/Board Member | 1 |
Undergraduate Degree | 1 |
Sectorielle
Health Technology | 3 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
IPSEN | Health Technology |
Entreprise privées | 3 |
---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Leem | |
Université de Paris XI Paris Sud | Consumer Services |
- Bourse
- Insiders
- Didier Véron
- Expérience